" . In the era of precision medicine, a . . comprehensive understanding of the mutational landscape of a disease is becoming crucial for drug development efforts. Gene editing has found its application in precision medicine, with the recent approval of world's first CRISPR–Cas9 gene editing therapy for sickle cell disease. The approval paves the way for treatments based on genome-editing technology to treat a wide variety of diseases.”
~ Dr. Murali Ramachandra
"The USFDA approval of Toripalimab marks a significant milestone for this rare ...............cancer type. This approval is a first in many ways – first and only immuno Oncology drug(PD1 immune checkpoint inhibitor) to be approved by USFDA for NPC, first Immune checkpoint inhibitor from China to be approved by USFDA, the first NBE in-licensed as part of our broader Innovative products strategy to foray into the Innovative NCE/NBE space. Dr.Reddy’s has partnered with Shanghai Junshi Biosciences for commercialisation of Toripalimab across 21 markets in EM and India.
The Nobel Prize for Medicine was awarded on Monday to Katalin Karikó and Drew Weissman, for discoveries that led to the development of mRNA vaccinations, including those developed during the Covid-19 pandemic.
“Dear Colleagues, In our ongoing quest for excellence, we must continually expose ourselves to the world of knowledge that surrounds us. We will be sharing with you a curated list of articles that touch upon critical areas in pharma science, market dynamics, technology and more. These readings, I believe, will strengthen not just our individual knowledge but also the collective wisdom of our organisation."
~G V Prasad
